Technology

For the life sciences industry in 2017, engaging across social media means less talking-and more listening.

Outlining the new communication priorities necessary to excel in the emerging outcomes-based healthcare landscape.

How artificial intelligence can help pharma filter out the online noise when monitoring for safety signals on the web.

Internal oversight and the tools to remain compliant are critical to companies seeking to avoid corporate integrity agreements (CIAs) or efficiently fulfill existing agreements. In either case, CIAs can be a business advantage, writes Gabriela P. Baron.

Cherry Cabading and Mona Rakibe outline how the use of modern data management techniques can help companies see improvements in sales effectiveness, data steward productivity and overall data quality.

A recent IT leadership survey found that many more pharma companies are reporting their digital strategies are ineffective compared to other industries. Heath Jackson looks at why this is – and what they need to do about it.

Pieter De Richter explores how the molecular diagnostics landscape-and the very way we think about fighting cancer-is set to change dramatically in the coming decades.

The health promises of big data will not be met unless the right technology is put in place to ensure that data can flow freely and fast across a WAN, writes David Trossell.

While it’s easy to get excited about new gadgets, remember that the overall goal of mHealth and social media must be to deepen relationships and communication.

Outlining the four core elements pharma companies need to lay the foundation for a solid digital health infrastructure.

The FDA's Mary Ann Slack outlines how the Agency is working to adopt electronic practices by initiating efforts to simplify the submission process for new drug and generic drug applications.

With digital interventions in drug adherence regimes evolving to new levels of sophistication, Pharm Exec looks at the ongoing patient-behavior and privacy issues that still present significant challenges.

The rapid development and take-up of digital technology is forever changing the way pharma engages with patients-but the industry’s ultimate potential in tapping digital health to transform patient care hinges on embracing new shifts in culture and business strategy.

Separating the meaningful from the merely novel, Bill Drummy outlines his Top Ten digital marketing trends for 2017.

With the physician-access climate as daunting as ever for sales reps, four best practices in implementing artificial intelligence-based technology to help achieve engagement wins are explored.

Q&A spotlights the development of one injection device that is helping change the treatment-adherence landscape.

Big data has proven to be a valuable business asset, but using it to gain competitive advantage requires the right combination of strategy, technology and execution, write Mahmood Majeed, Vickye Jain, and Sandeep Varma.

Multi-channel marketing manager Adi Borovick discusses the implications of compliance for marketers in a world where new technologies being created every day.

In the 21st Century Cures Act, Congress excluded from FDA regulation certain clinical decision support, or CDS, software.

Pharm Exec speaks to Andrew Marr about the implications of the European Union's new IDMP (Identification of Medicinal Products) regulations for the pharma industry.

The digital workplace is defined as a “business strategy to boost employee engagement and agility through a more consumerized work environment”. But what exactly does this mean for life sciences organizations? Michael Woodbridge explains.

It’s no longer sufficient for a pharma to develop better products or even build simple apps. The industry increasingly needs to create sophisticated predictive algorithms to maximize the ability of its products, write Tom Agan and Fred Geyer.

Emil Eifrem examines how life science researchers can uncover new insights using the in-built power of graph technology.